MedTrace Logo

Lenalidomide for Adult Histiocyte Disorders

NCT02523040 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-12-10

Study results available
· View outcomes & findings →

Summary

This research study is studying a chemotherapy drug Lenalidomide as a possible treatment for one of three histiocyte disorders: Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), or histiocytic sarcoma (HS).

Conditions

  • Langerhans Cell Histiocytosis (LCH)
  • Histiocytoses Erdheim-chester Disease
  • Histiocytic Sarcoma (HS)

Interventions

DRUG

Lenalidomide

Sponsors & Collaborators

Principal Investigators

  • Eric Jacobsen, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2024-02-29
Completion
2026-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02523040 on ClinicalTrials.gov